Lipocine to Present at The H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

Lipocine Inc. (NASDAQ: LPCN) will present at the H.C. Wainwright 23rd Annual Global Investment Conference virtually from September 13-15, 2021. The presentation is scheduled for September 13, 2021, starting at 7:00 a.m. EST. Investors can access the webcast through the conference portal or Lipocine's website. The presentation will be available on-demand for 90 days. Lipocine focuses on metabolic and endocrine disorders, with products like TLANDO and LPCN 1144 addressing various testosterone-related conditions.

SALT LAKE CITY, Sept. 1, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.

H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

Presentation time: September 13, 2021 starting at 7:00 a.m. EST
Webcast link: https://journey.ct.events/view/6ad0ee65-750c-40c8-974f-d653d6d67c25

A webcast of Lipocine's presentation will be available on-demand as of 7:00 am ET, Monday, September 13, 2021, thorough the H.C. Wainwright conference portal, on Lipocine's website under "Events & Presentations" in the Investors section or using the webcast link above.  The webcast will be available on the Lipocine's website for 90 days. 

About Lipocine
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1107 and LPCN 1154. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, has received tentative approval from the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. LPCN 1144, an oral prodrug of bioidentical testosterone, recently completed a Phase 2 clinical study demonstrating the potential utility in the treatment of non-cirrhotic NASH.   TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. In a phase 2 clinical evaluation when administered as once daily or twice daily TLANDO XR met the typical primary and secondary end points. LPCN 1148 is an oral prodrug of bioidentical testosterone targeted for the treatment of cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. LPCN 1154 is an oral neuro-steroid targeted for the treatment of post-partum depression.  For more information, please visit www.lipocine.com. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lipocine-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-301366743.html

SOURCE Lipocine Inc.

FAQ

When is Lipocine presenting at the H.C. Wainwright conference?

Lipocine will present on September 13, 2021, at 7:00 a.m. EST.

What is the schedule for the H.C. Wainwright 23rd Annual Global Investment Conference?

The conference will be held virtually from September 13-15, 2021.

Where can I watch Lipocine's presentation?

The presentation can be watched via a webcast link provided on Lipocine's website and the conference portal.

How long will Lipocine's presentation be available on-demand?

The presentation will be available on-demand for 90 days.

What is Lipocine's focus as a biopharmaceutical company?

Lipocine focuses on metabolic and endocrine disorders, utilizing proprietary drug delivery technologies.